



Published in final edited form as:

Mol Psychiatry. 2019 May ; 24(5): 694–709. doi:10.1038/s41380-018-0219-x.

Cholinergic Regulation of Mood: From Basic and Clinical Studies to Emerging Therapeutics

Stephanie C. Dulawa, Ph.D.^{1,*}, David S. Janowsky, M.D.¹

¹Department of Psychiatry, University of California at San Diego

Abstract

Mood disorders are highly prevalent and are the leading cause of disability worldwide. The neurobiological mechanisms underlying depression remain poorly understood, although theories regarding dysfunction within various neurotransmitter systems have been postulated. Over 50 years ago, clinical studies suggested that increases in central acetylcholine could lead to depressed mood. Evidence has continued to accumulate suggesting that the cholinergic system plays an important role in mood regulation. In particular, the finding that the antimuscarinic agent, scopolamine, exerts fast-onset and sustained antidepressant effects in depressed humans has led to a renewal of interest in the cholinergic system as an important player in the neurochemistry of major depression and bipolar disorder. Here, we synthesize current knowledge regarding the modulation of mood by the central cholinergic system, drawing upon studies from human postmortem brain, neuroimaging, and drug challenge investigations, as well as animal model studies. First, we describe an illustrative series of early discoveries which suggest a role for acetylcholine in the pathophysiology of mood disorders. Then, we discuss more recent studies conducted in humans and/or animals which have identified roles for both acetylcholinergic muscarinic and nicotinic receptors in different mood states, and as targets for novel therapies.

INTRODUCTION

Mood disorders are the leading cause of disability worldwide. Two major categories of mood disorder, major depression and bipolar disorder, are estimated to occur in the general population at rates of 18% and 2–3%, respectively^{1–3}. Dysfunction within various neurotransmitter systems, including the serotonergic, noradrenergic, dopaminergic, GABAergic, glutamatergic, and endorphinergic systems have been hypothesized to underlie mood disorders due to the mechanism of action of pharmacological treatments that target these systems, and biological findings^{4–6}. The recent finding that the antimuscarinic agent, scopolamine, induces fast-onset and sustained antidepressant effects in depressed patients has renewed interest in understanding the role of the cholinergic nervous system in mood regulation^{7–11}.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

*Corresponding author: Stephanie Dulawa, Ph.D., Associate Professor in Psychiatry, University of California San Diego, 9500 Gilman Drive, Mailcode 0804, La Jolla, CA 92093-0804, USA (sdulawa@ucsd.edu).

Conflict of interest:

Drs. Dulawa and Janowsky declare no conflict of interest.

As early as 1950, clinical research observations suggested that increases in central acetylcholine (ACh) could lead to depressed mood^{12–14}. In the 1970s, this possibility was further elaborated as the adrenergic-cholinergic balance hypothesis of mania and depression¹⁵. As proposed by Janowsky et al. (1972), this hypothesis posited that depression involved a central predominance of acetylcholinergic to noradrenergic tone, while mania resulted from the converse¹⁵. This theory was then reformulated as the catecholaminergic-cholinergic balance hypothesis of mania and depression, which integrated more recent findings incorporating the role of dopamine, a neurotransmitter integral to the regulation of mood¹⁶.

Since the role of catecholamines, and dopamine in particular, have been reviewed previously^{17–19}, this review will primarily summarize current knowledge regarding the modulation of mood by the central cholinergic system. Human postmortem brain, neuroimaging, drug challenge, and animal model studies have examined the role of the cholinergic system in mood regulation. Here, we first describe an illustrative series of early discoveries which have suggested a role for acetylcholine in the pathophysiology of mood disorders. We will then discuss more recent studies conducted in humans and/or animals which have investigated the role of acetylcholinergic muscarinic and nicotinic receptors in different mood states, and as targets for therapeutics.

CHOLINERGIC REGULATION OF MOOD

Acetylcholinesterase Inhibitors, ACh receptor agonists, and ACh Precursor Effects on Mood in Humans

The earliest observations of a potential link between acetylcholine and depression were based on clinical observations of the effects of ACh receptor (AChR) agonists, which activate AChRs, and acetylcholinesterase inhibitors (AChEIs), which prevent the breakdown of ACh by acetylcholinesterases (AChEs). AChEIs compose a class of insecticides used in agriculture, and nerve agents used in wartime. Exposure to AChEIs increases acetylcholine levels in both the central nervous system and the periphery, causing toxic and potentially lethal respiratory, central nervous system, and cardiovascular effects.

Several early reports indicated that individuals exposed to AChEI insecticides or potential nerve agent weapons developed psychiatric symptoms including psychotic phenomena, anxiety, and most commonly, depression. In 1950, Rowntree et al. found that administration of the irreversible AChEI diisopropylfluorophosphate (DFP) to bipolar patients reduced manic symptoms and induced depression¹². Furthermore, when administered to normal or depressed patients, DFP increased depressive symptoms and in some, activated psychotic symptoms. Gershon and Shaw (1961) reported that agricultural workers chronically exposed to AChEI insecticides became depressed or psychotic¹³. Bowers et al. (1964) tested the AChEI, EA 1701, in army volunteers and reported onset of depression¹⁴. Moreover, early animal behavioral pharmacological studies reported similar findings. For example, both the cholinergic muscarinic agonist arecoline and the AChEI physostigmine reduced rodent intracranial self-stimulation (ICSS), a measure of reward threshold^{20, 21}.

Subsequently, a number of investigators formally studied the psychiatric and behavioral effects of AChEI challenges (Table 1). Janowsky et al. (1973) reported that in patients with bipolar or major depressive disorder, an acute challenge with the centrally active and reversible AChEI, physostigmine, antagonized manic symptoms and induced depressive symptoms, including apathy, slowness of thought, and psychomotor retardation²². Similar studies replicated the antimanic effects of physostigmine in bipolar patients^{23, 24}. Furthermore, an acute physostigmine challenge also precipitated depressive symptoms in psychiatric inpatients, especially those with a history of major depression²². Other reports indicated that physostigmine treatment also induces depressive symptoms in a minority of control subjects^{25–27}. Recently, the AChEI donepezil was reported to induce more frequent relapse of depression in older patients with mild cognitive impairment^{28, 29}. Furthermore, Altinyazer et al. (2016) showed that among individuals with major depression living in agricultural districts, red blood cell acetylcholinesterase activity levels negatively correlated with the number of past suicide attempts and hopelessness levels³⁰. These reports are consistent with more recent SPECT imaging studies suggesting that levels of acetylcholine are increased throughout the brain in depressed unipolar and bipolar patients³¹. Thus, considerable evidence suggests that AChEIs reduce elevated mood during mania, increase depressive symptoms in depressed patients, and induce depression in euthymic individuals with a personal or family history of depression.

Acetylcholine precursors, such as deanol, choline, and lecithin, have also been reported to cause depression, and paradoxically hypomania in some cases. Tamminga et al. (1976) reported that choline precipitated depression in 2 out of 4 patients with tardive dyskinesia³², and Growdon et al. (1977) reported that 2 out of 20 patients with tardive dyskinesia became withdrawn and apathetic³³. Casey (1979) reported that high doses of deanol caused severe depression in 5 out of 33 movement disorder patients, and 3 of the 33 became hypomanic³⁴. Overall, patients who developed mood symptoms had a history of affective disorder. Subsequent studies with the AChergic precursor citicoline showed mixed effects, with either no mood effects or reduced depressive symptoms when given along with agents including rivastigmine, citalopram, or lithium^{35,36,37,38}.

Procholinergic Agents Induce Biomarkers of Depression in Humans

Cholinergic agents including AChEIs and muscarinic agonists have also been reported to influence the expression of biomarkers linked to mood disorders, including effects on neuroendocrine measures, sleep, and pupillary size. Serum levels of adrenocorticotrophic hormone (ACTH)^{39, 40}, cortisol^{41–43}, and beta endorphin^{44–46}, have been reported to be increased in depressed patients, as has cortisol non-suppression by dexamethasone. Similarly, increasing acetylcholine levels with physostigmine treatment has been reported to increase serum ACTH, cortisol, and beta endorphin^{27, 47, 48}. Furthermore, physostigmine-induced increases in ACTH and beta endorphin were exaggerated in depressed patients compared to normal volunteers⁴⁹. Physostigmine also induced non-suppression of cortisol by dexamethasone in normal adults⁵⁰. Subsequently, a sex difference was reported in which low doses of physostigmine increased serum levels of ACTH and cortisol in females with a history of depression⁵¹, but not in males.

Specific changes in sleep architecture are also endophenotypic markers of clinical depression observed in depressed patients and their asymptomatic relatives⁵². These changes include increases in rapid eye movement (REM) sleep duration, increases in REM density, reductions in REM latency, decreases in slow wave sleep, and disturbances in sleep continuity^{52, 53, 54, 55}. These sleep alterations result in part from perturbations in the cholinergic system, with procholinergic influences inducing depression-relevant sleep effects⁵⁶. Thus, the AChEI, galantamine, increases REM tonic activity and decreases REM latency⁵⁷. Administration of procholinergic agents including physostigmine⁵⁸, donepezil⁵⁹, arecoline^{60–63}, or pilocarpine^{64, 65} to controls reduces REM latency, and increases REM density. Furthermore, Laurer et al. (2004) found that the cholinergic muscarinic agonist RS 86 induced REM latency super-shortening in high risk individuals without a history of depression, and this was a predictor of a subsequent first major depressive episode⁶⁶. Similarly, Perlis et al. (2002) discriminated control versus depressed patients by their response to donepezil. Controls showed no REM latency changes following low dose treatment, whereas depressed patients showed decreased REM latency⁶⁷. Similarly, asymptomatic relatives of depressed patients showed a parallel vulnerability to cholinergic stimulation⁶⁷. Furthermore, vulnerability to physostigmine-induced REM hypersensitivity is highly correlated in monozygotic twins, suggesting a genetic component to this phenomenon⁶⁸.

In contrast to the effects of cholinomimetic agents on sleep, several reports have indicated that the centrally active antimuscarinic, scopolamine, increases REM latency and suppresses REM density and duration in depressed patients^{69, 70}. Furthermore, these scopolamine effects are evident following remission⁷¹. Thus, antagonizing muscarinic receptors produces effects on REM sleep that are opposite of those observed in depressed patients.

Another biomarker observed in depressed patients is pupillary sensitivity to cholinergic agonists. Depressed patients exhibited significantly greater reductions in pupillary diameter following administration of the muscarinic agonist pilocarpine than did controls, suggesting increased muscarinic sensitivity⁷². Conversely, a report by Sokolski and DeMet (2000) showed decreased pupillary sensitivity to pilocarpine in manic patients, a phenomenon which was reduced with lithium treatment⁷³.

AChEIs and ACh Agonist Effects on Mood in Rodents

Similar to findings in humans, a number of rodent studies have also demonstrated that treatment with AChEIs or cholinergic agonists induce depression-like behaviors (Table 2). Picciotto and colleagues, as well as others, have shown that systemic administration of physostigmine to mice increases depression-like behaviors including social avoidance following social defeat⁷⁴, immobility in the forced swim test (FST)^{75–77}, and immobility in the tail suspension test (TST)^{76, 78}. Furthermore, some of these pro-depressive effects were more pronounced in male than female mice^{76, 77}. The pro-depressive effects of systemic physostigmine treatment in the TST were blocked by acute treatment with either scopolamine, a broad muscarinic antagonist, or mecamylamine, a broad nicotinic antagonist⁷⁴. Additionally, physostigmine treatment increased anxiety-like behavior in mice, including time spent in the dark side of the light/dark box, and time spent in the center of the

open field^{76, 77}. Treatment with either physostigmine or pilocarpine also decreased rates of intracranial self-stimulation (ICSS) of the ventral tegmental area (VTA), reflecting increased anhedonia⁷⁹. These depressogenic effects of physostigmine are observed despite tight regulation of AChE through negative feedback pathways at the mRNA, protein, and activity levels. For example, significant adaptation has been observed following knockout of AChE isoforms⁸⁰, and exposure to AChEIs leads rapidly to upregulation of AChE mRNAs⁸¹. Furthermore, stress induces alternative splicing of AChE mRNAs and modulation of AChE activity^{82, 83}.

Local intracerebral drug infusion studies in rodents have implicated several brain regions in the depressogenic effects of procholinergic drug treatments. For example, intra-VTA infusion of physostigmine increased immobility time in the FST⁷⁵, decreased time spent on open arms in the elevated plus maze, and decreased sucrose preference⁸⁴, indicating increased anxiety and anhedonia, respectively. Furthermore, intra-VTA infusion of pilocarpine produced similar effects⁸⁴. Conversely, intra-VTA infusion of scopolamine or mecamylamine decreased baseline immobility time in the FST, indicating antidepressant-like effects⁷⁵.

Mineur et al. (2013) assessed the effects of chronic fluoxetine treatment on AChE activity in multiple brain regions, and found that chronic fluoxetine increased AChE activity, specifically in the hippocampus⁷⁴. To test the hypothesis that signaling at Ach receptors could contribute to depression-like behavior, physostigmine was infused locally into the hippocampus and behavior in the TST was assessed. Consistent with this hypothesis, intra-hippocampal physostigmine increased immobility, reflecting depression-like behavior⁷⁴. Additionally, knockdown of AChE in the hippocampus using an adeno-associated virus (AAV) approach increased anxiety in the open field test and the light/dark test, and increased depression-like behavior in the FST, TST, and social defeat paradigm⁷⁴. Additionally, 15 days of treatment with fluoxetine prevented the effects of viral hippocampal AChE knockdown in the social defeat paradigm⁷⁴.

Work by Chau et al. (2011) suggests that fluoxetine treatment produces antidepressant-like effects in the FST by reducing cholinergic activity in the nucleus accumbens (NAc)⁸⁵. Specifically, intra-NAc infusions of fluoxetine reduced extracellular acetylcholine and increased active behavior in the FST⁸⁵. Furthermore, exposure to the FST, a potent stressor, increased basal extracellular acetylcholine in the NAc shell for up to 14 days, while chronic fluoxetine treatment prevented this effect⁸⁵. Similarly, intra-NAc infusions of the muscarinic acetylcholine receptor (AChR) agonist arecoline reduced active behavior⁸⁶, and intra-NAc infusions of neostigmine produced a conditioned taste aversion⁸⁷. This depressant-like effect may be mediated in part through activation of muscarinic 1 acetylcholine receptors (M1-AChRs)⁸⁸, since blocking these postsynaptic receptors with the specific M1-AChR antagonist pirenzepine increased swimming in the FST⁸⁶. On the other hand, activation of M2 acetylcholine autoreceptors, which are Gi-coupled, reduces ACh release and has antidepressant-like effects. Accordingly, the acetylcholine M2-AChR antagonist gallamine induces pro-depressant effects⁸⁶. Finally, intra-NAc infusion of scopolamine increases active behavior in the FST, indicating an antidepressant-like effect⁸⁶. However, Warner-Schmidt et al. (2012) reported that silencing cholinergic interneurons in the NAc induced a depression-

like phenotype in mice⁸⁹. Since the cholinergic interneurons of the NAc synapse locally onto other neurons within the NAc, and are the only source of ACh in the striatum, these results appear to contrast with findings that intra-NAc scopolamine infusions produced antidepressant effects⁸⁶. This inconsistency might be explained by the positioning of cholinergic interneurons within microcircuits of the NAc, which theoretically could preferentially influence M2-over M1-AChRs. In sum, AChRs in the VTA, hippocampus, and NAc appear to regulate depression-like behaviors in rodent models.

Muscarinic Effects of Physostigmine and Arecoline in Humans

Early studies suggested that muscarinic AChRs (M-AChRs) are important for the mood altering effects of acetylcholine. The depressogenic effects of low dose physostigmine were reversed by administration of atropine, a centrally active antimuscarinic agent⁹⁰, or scopolamine⁹¹. Direct muscarinic agonists have also been reported to reduce mood. Specifically, the direct muscarinic agonists arecoline^{92, 93}, and oxotremorine⁹⁴ worsened mood state in both euthymic and bipolar patients. Similarly, the M1-AChR agonist, RS 86, was reported to have antimanic effects⁹⁵.

Similarly, a series of studies specifically investigated whether the depression-like effects of physostigmine are mediated by muscarinic receptors, and whether these effects are mediated centrally or peripherally. Studies dissecting the mechanisms of action of physostigmine on behavioral, neuroendocrine, cardiovascular, and sleep measures have largely implicated central muscarinic receptors in these actions. Whereas centrally acting physostigmine causes significant behavioral, neuroendocrine, cardiovascular, and sleep effects in humans, equipotent doses of the non-centrally acting AChEI, neostigmine, does not^{91, 96, 97}. Furthermore, these effects of physostigmine can be blocked by the centrally acting antimuscarinic agent, scopolamine⁹¹, which is a high affinity antagonist at the five known muscarinic receptors and does not act at nicotinic receptors⁹⁸. The effects of physostigmine are not prevented by treatment with the peripherally acting antimuscarinic agent, methscopolamine⁹¹, suggesting a central effect.

Muscarinic Receptor Alterations in Mood Disorders

A body of research has explored central muscarinic receptor expression in controls, depressives and/or bipolar patients using in vivo imaging, positron emission tomography (PET), or radioligand binding in postmortem brain samples. Several reports have identified a reduction in M2-AChR and M4-AChR density in both bipolar and major depressive disorder patients. Activation of M2-AChRs or M4-AChRs, which are autoreceptors, reduces acetylcholine release from cholinergic terminals⁹⁹. Thus, reduced expression of these receptors might increase Ach release. Cannon et al. (2006) used PET imaging to investigate central M2-AChR receptor density using [(18)F]FP-TZTP in unmedicated major depressive and bipolar disorder patients. They found that bipolar patients showed a lower distribution volume of M2-AChR in the anterior cingulate cortex (ACC) compared to both major depressive disorder and control groups¹⁰⁰. This decrease in distribution volume could have resulted from reduced M2-AChR density or affinity, or increased endogenous acetylcholine levels which could reduce radioligand binding to M2-AChRs. Indeed, increased central choline levels have been found in depressed patients^{101, 102}. Studies applying the M2/4

receptor antagonist, [3H] AFDX-384, to post-mortem brain tissue from patients with major depressive or bipolar disorder also reported reduced M2-AChR and M4-AChR binding in Broadman's area 46 of the dorsolateral prefrontal cortex¹⁰³. Furthermore, a decrease in binding of the M3-AChR antagonist, [3H]4-DAMP, in Broadman's area 10 indicated a decrease in M3-AChR expression in the rostral prefrontal cortex in bipolar patients¹⁰³. More recently, Gibbons et al. (2016) measured M2-AChR and M4-AChR binding in Broadman's Area 24 and 46 of the dorsolateral prefrontal cortex using post-mortem tissue from controls, bipolar disorder patients, or major depressive patients¹⁰³. Results showed that both M2-AChR and M4-AChR binding was lower in Broadman's area 24 and 46 of the dorsolateral prefrontal cortex in mood disorder patients relative to controls.

However, other reports have not replicated muscarinic receptor density changes in depression or bipolar disorder. For example, Zavitsanou et al (2005) assessed [(3)H]AF-DX 384 binding in the ACC to determine M2-AChR and M4-AChR binding in control, major depression, and bipolar patients¹⁰⁴. However, no differences in receptor binding were found. Furthermore, an experiment using quantitative autoradiography to measure [(3)H]pirenzepine binding to M1-AChR and M4-AChR receptors in post-mortem tissue also found no difference in binding in bipolar and major depression groups compared to controls¹⁰⁵. Additionally, a study using a [3H]4-DAMP radioligand binding assay which was modified to increase selectivity for the M3-AChR showed that cortical M3-AChR levels were not altered in major depression or bipolar disorder¹⁰⁶. Heterogeneity in the etiology underlying mood disorders may be a factor leading to discrepant findings between studies^{107, 108}.

ANTIMUSCARINIC TREATMENT STUDIES

Fast-onset Antidepressant Effects of Scopolamine in Humans

In the early 1980's, Janowsky et al. (1983) proposed that centrally active anticholinergic drugs might be effective antidepressants^{109, 110}. Although anticholinergics were reported to cause a "high" in recreational users¹¹¹⁻¹¹³, and scopolamine was found to be effective in antagonizing the behavioral, cardiovascular, sleep, and neuroendocrine effects of AChEIs⁹¹, definitive proof that anticholinergics like scopolamine alleviated depression in humans remained elusive. In the next two decades, several randomized controlled trials (RCTs) assessed the effects of scopolamine or the antimuscarinic biperiden in depressed patients, but did not conclusively identify antidepressant effects of these drug treatments^{114, 115}. However, Gillin et al. (1991) reported a small but significant antidepressant effect of scopolamine administered intramuscularly for three consecutive nights compared to placebo¹¹⁶.

Studies published beginning in the mid-2000s by the National Institute of Mental Health (NIMH) Intramural Mood and Anxiety Disorders Program demonstrated that when administered at a higher dosage by the intravenous (i.v.) route, 4 µg/kg scopolamine exerted fast-onset antidepressant effects. After an open placebo infusion, major depressive disorder and bipolar patients received a series of three 15 min infusions of placebo followed by a series of three infusions of scopolamine, or the reverse sequence, each infusion pulsed 3-5 days apart. The placebo adjusted remission rate with scopolamine was 56%, with an onset of

3 days, persisting for at least 15 days⁷. Anti-cholinergic side effects were well tolerated. The same group replicated these findings in a major depressive group. Results showed that scopolamine also decreased anxiety, and produced larger reductions in anxiety symptoms in women than men⁹. Subsequent trials by the NIMH group have also shown the rapid-onset antidepressant effects of i.v. scopolamine, and identified characteristics of responders. Scopolamine induced antidepressant effects in treatment resistant major depressive and bipolar patients, and also produced larger antidepressant effects in treatment naïve patients¹¹. Furthermore, scopolamine was more effective in patients with greater self-rated depressive symptoms at baseline¹⁰. In summary, i.v. infusion of scopolamine has been identified as a rapid-onset antidepressant with sustained effects for major depression and bipolar disorders. Also, one study by Khajavi et al. (2012) reported antidepressant effects of orally administered scopolamine. This study evaluated whether scopolamine could augment the effects of a classical antidepressant in major depressive disorder patients. In this RCT, a combination of the SSRI antidepressant citalopram (40 mg/day) plus oral scopolamine hydrobromide (1 mg/d) for six weeks was more effective (65% remission) than citalopram plus placebo (20% remission)¹¹⁷.

Although a number of RTCs have demonstrated fast-onset antidepressant effects of scopolamine infusion in patients with unipolar or bipolar depression, none have reported any effects on mania symptoms. Based on the catecholaminergic-cholinergic balance hypothesis of mania and depression, scopolamine treatment might be expected to not only reduce depression, but possibly increase mania symptoms. The catecholaminergic-cholinergic balance hypothesis is also supported by work in rodents showing antidepressant-like effects of scopolamine treatment in normal or stressed animals. Future RTCs should be designed to assess the effects of scopolamine infusion on manic or hypomanic symptoms in bipolar patients, including those with rapid cycling.

Fast-onset Antidepressant-like Effects of Scopolamine in Rodents

A number of recent studies in rats and mice have shed light on the mechanisms by which scopolamine induces fast-onset antidepressant-like effects^{118–121}. Similar to ketamine, a single, low dose injection of scopolamine in rodents rapidly induces an antidepressant-like behavioral response in several paradigms, including the FST^{118–121}, the chronic mild stress paradigm¹¹⁹, the novelty-induced feeding paradigm^{118, 120}, the sucrose preference test¹¹⁹, and learned helplessness^{122, 123}. Acute scopolamine treatment induces molecular changes in the medial prefrontal cortex (mPFC). These effects include induction of brain-derived neurotrophic factor (BDNF) release¹¹⁸, activation of mammalian target of rapamycin complex 1 (mTORC1), and increases in the number and function of spine synapses in layer V pyramidal neurons in the mPFC. These molecular changes induced by scopolamine have also been implicated in the fast-onset antidepressant effects of ketamine^{124–126}. Pretreatment with a mTORC1 inhibitor or by a glutamate alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonist blocks the antidepressant effects of scopolamine¹²¹. Scopolamine has been reported to initiate this molecular cascade by antagonizing the M1-AChR in the mPFC. Although both GABAergic (GAD67+) interneurons and glutamatergic (CaMKII+) interneurons in the mPFC express M1-AChR, viral-mediated knockdown of M1-AChR in GABAergic, but not glutamatergic, neurons

diminishes the antidepressant-like effects of scopolamine¹²⁰. Further immunohistological and electrophysiological studies have shown that somatostatin interneurons in the mPFC highly express M1-AChR, and receptor knockdown studies demonstrated that M1-AChR expression in these neurons is required for the rapid antidepressant-like effects of scopolamine¹²⁰. In addition, the antagonism of M1-AChR on somatostatin interneurons in the mPFC results in disinhibition of pyramidal glutamatergic neurons, leading to a burst of glutamate and downstream molecular pathways thought to mediate the antidepressant response through synaptogenesis¹²⁰. More details regarding the molecular mechanisms mediating the rapid-onset antidepressant-like effects of scopolamine in rodents has been reviewed elsewhere¹¹⁸.

The role of M2-AChRs in the mechanism of antidepressant action of scopolamine has also been investigated. Studies using M1-AChR or M2-AChR knockout mice treated with agonists that are preferentially selective for each of these receptors have shown that antagonists of M2 receptors, as well as M1 receptors, induce antidepressant-like effects¹²⁷. Conversely, mice lacking M3-AChRs, M4-AChRs, or M5-AChRs do not show a reduced antidepressant-like response to scopolamine¹²⁷. Thus, work to date suggests that M1-AChRs, and likely M2-AChRs, mediate the antidepressant-like effects of acute scopolamine treatment.

NICOTINIC REGULATION OF MOOD:

Nicotinic Treatment Studies in Humans:

Evidence suggests that nicotinic receptors also contribute significantly to the regulation of mood. Nicotine withdrawal due to cigarette smoking cessation has been well established to induce depression, anxiety, and dysphoria, which may continue for as long as 10 weeks^{128, 129}. This especially occurs in subjects with a history of major depression^{130, 131}. Furthermore, administration of nicotine using transdermal patches has been shown to alleviate depression during smoking cessation¹³². However, controlled studies assessing the effects of nicotine on depression in non-smokers are very rare. Of those, McClernon et al. (2006) found that chronic nicotine administration by patch produced antidepressant effects in non-smokers, compared to placebo¹³³. Furthermore, Salin-Pascual et al. (1996) noted improvement in mood in major depression patients after only 2 days of treatment with nicotine patches¹³⁴. Observations of improved mood following nicotine treatment^{134, 135}, or smoking, have led to the hypothesis that smoking nicotine tobacco is sometimes used to self-medicate symptoms of depression¹³⁶.

A small number of controlled studies have examined the effects of nicotinic agents besides nicotine in depressed patients. One study assessed the ability of CP-601,927, an $\alpha 4\beta 2$ nicotinic acetylcholine receptor (nAChR) partial agonist, to augment a sub-optimal antidepressant response to SSRIs; however, no therapeutic effect was found¹³⁷. Furthermore, a meta-analysis of six randomized-controlled trials including 2067 participants failed to confirm preliminary positive evidence for the efficacy of nAChR antagonists in treatment-resistant depression¹³⁸. For example, the non-selective, non-competitive antagonist of nAChRs, desmethylamine (TC-5214) failed Phase III trials as a treatment for major depression¹³⁹. Although no agents acting primarily at nicotinic receptors are currently in use

for the treatment of depression, it should be noted that many current antidepressants including tricyclics, SSRIs, and bupropion also act as $\alpha 4\beta 2$ nAChR antagonists in cell-based assays^{140, 141}.

Nicotinic Treatment Studies in Rodents

Nicotine withdrawal-induced anhedonia in rodents provides a well validated model for aspects of major depression¹⁴². For example, the affective aspects of nicotine withdrawal can be assessed in rats and mice as elevations in brain-stimulation reward thresholds and conditioned place aversion. nAChR subtypes including the $\alpha 5$, $\alpha 2$, $\alpha 3$, and $\beta 4$ subunits have been implicated in the aversive properties of nicotine withdrawal^{143–146}. Furthermore, nicotine self-administration in rats results in an increase in the sensitivity of natural brain reward systems, detected by post-nicotine lowering of intracranial self-stimulation (ICSS) thresholds¹⁴⁷. Surprisingly, nicotine-induced excitation of reward systems has been reported to persist for at least 36 days after cessation of nicotine self-administration had ceased¹⁴⁷. Since nicotine increases serotonergic and noradrenergic neuronal activity and facilitates serotonin and noradrenaline release, the effects of coadministration of nicotine with SSRIs or noradrenaline reuptake inhibitors (NRIs) have been explored in preclinical studies. For example, nicotine enhances the antidepressant-like effects of low-dose citalopram or reboxetine in the FST in mice¹⁴⁸. In addition, chronic mild stress-induced anhedonia can be alleviated by either nicotine or sertraline, but the two treatments did not have a synergistic effect¹⁴⁹.

Human Studies of Nicotinic Receptors

Like muscarinic receptors, nicotinic receptor function has also been reported to be altered in depressed patients. Single-photon emission computed tomography (SPECT) studies have found a reduction of $\beta 2$ subunit-containing nAChR ($\beta 2^*$ nAChR) availability across all brain regions in major depression patients compared to healthy controls. Furthermore, acutely depressed patients in this study were also found to have lower $\beta 2^*$ nAChR availability than remitted patients³¹. This reduction in $\beta 2^*$ nAChR availability in depressed patients has been suggested to result from increased central acetylcholine levels, which reduce the number of receptors available for binding to a SPECT ligand. For example, a SPECT study by Esterlis et al. (2013) showed that increases in ACh levels induced by physostigmine challenge reduces SPECT ligand binding¹⁵⁰. Furthermore, a negative correlation between lifetime number of depressive episodes and $\beta 2^*$ nAChR availability in temporal cortex, occipital cortex, thalamus, and striatum was reported in patients with major depressive disorder³¹. Consistent with findings in patients with major depression, a SPECT imaging study using [(123)I]5IA-85380 to quantify $\beta 2^*$ nAChR total volume of distribution found significantly lower $\beta 2^*$ nAChR availability (20–38% less) in subjects with bipolar depression compared to euthymic patients and controls in frontal, parietal, temporal, anterior cingulate cortex, hippocampus, amygdala, thalamus, and striatum¹⁵¹. In contrast, post-mortem studies using acetylcholine washout showed identical $\beta 2^*$ nAChR density in controls, major depression patients, and bipolar disorder patients. Therefore, depressed and bipolar patients likely have increased endogenous acetylcholine levels but similar $\beta 2^*$ nAChR expression levels relative to controls.

Rodent Studies of Nicotinic Receptors

Rodent studies have also implicated nicotinic receptors in the regulation of depression-like behavior. However, differences between rats and mice have been found, with the antidepressant effects of nicotine being observed more frequently in rats. Nicotine treatment has antidepressant-like effects in several animal models of depression-like behavior, including the FST^{152, 153}, the TST¹⁵⁴ and the olfactory bulbectomy model¹⁵⁵. Yet, the non-selective, non-competitive nicotinic antagonist mecamylamine also produces antidepressant-like effects in the FST in rodents^{148, 156}, a result which was not due to a generalized stimulant effect¹⁵⁷. Furthermore, in rats exposed to chronic restraint stress, mecamylamine blocked depression-like behaviors including reductions in sucrose preference, increased anxiety, and hypothalamic pituitary adrenal hyperactivity¹⁵⁸. However, a meta-analysis including six randomized-controlled trials examining effects of nAChR antagonists in treatment-resistant depression found no antidepressant effects¹³⁸.

Rodent studies suggest that targeting specific nAChR subtypes might provide a therapeutic strategy for treating depression¹⁵⁹. Nicotinic antagonists at $\beta 2^*$ or $\alpha 7$ nAChRs have been reported to have antidepressant-like effects in mice. The $\alpha 7$ nAChR antagonist methyllycaconite reduced immobility in the FST and TST, and decreased physostigmine-induced c-fos immunoreactivity in the hippocampus. These effects were observed in male, but not female, mice⁷⁶. The $\alpha 4\beta 2$ nAChR partial agonist varenicline showed antidepressant-like activity in the FST in two mouse strains, and also enhanced the effects of the SSRI sertraline¹⁶⁰; $\alpha 4\beta 2$ nAChR partial agonists may induce antidepressant-like effects by inducing dopamine release from VTA-NAc projections¹⁶¹. Furthermore, one small open-label study of varenicline augmentation was associated with significant improvement in mood in outpatient smokers with persistent depression¹⁶². However, the $\alpha 4\beta 2$ nAChR partial agonist, CP-601,927, which was derived from varenicline, was not found to be effective in mouse models of antidepressant efficacy¹⁶³.

In a series of studies, Mineur et al. (2016) showed that viral-mediated knockdown of either the $\beta 2^*$ or $\alpha 7$ nAChR subunit within specific brain regions induced robust antidepressant-like effects in several behavioral tests. Specifically, $\alpha 7$ subunit knockdown in the amygdala produced antidepressant-like effects in the TST¹⁵⁹, while $\beta 2^*$ subunit knockdown produced antidepressant-like effects in the FST, TST, and the social defeat paradigm¹⁵⁹. $\beta 2^*$ subunit knockdown in the amygdala was also found to be critical for the antidepressant-like effects of the alpha2-noradrenergic receptor agonist guanfacine, while the antidepressant-like effects of the nicotinic partial agonist cytisine required noradrenergic signaling in the amygdala, highlighting an interaction between ACh and noradrenergic signaling in the regulation of depression-like behaviors in the mouse¹⁶⁴. Furthermore, ACh signaling through $\alpha 7$ nAChRs in the hippocampus was reported to regulate depression-like behaviors when ACh levels are increased, which can occur under stressful conditions⁷⁶. More work in humans and animals will be required to determine which nAChR subtypes provide the most promising targets for the treatment of mood disorders.

DISCUSSION:

We have highlighted a number of experiments which suggest that increasing central acetylcholine causes depression in humans and depression-like behaviors in animals. These results are remarkably consistent across species, and suggest that blocking or lowering acetylcholinesterase activity, increasing central acetylcholine levels, or stimulating specific cholinergic receptors, all lead to depression^{15, 23, 24}. Furthermore, depression can be rapidly alleviated in humans by the pan-muscarinic receptor blocking agent, scopolamine^{7, 9–11}. Depression-like behavior is also rapidly reduced by acute scopolamine treatment in rodent models^{118–122}. Preclinical studies in rodents have made progress in understanding the specific muscarinic receptors, neural circuits, and molecular mechanisms by which altering cholinergic neurotransmission regulates affect^{74, 76, 118–121, 159}, and may provide novel therapeutics for mood disorders.

Work to date has also revealed an important role for nicotinic receptors in mood regulation. Extensive evidence has shown that nicotine withdrawal in both humans and animals produces a syndrome which includes symptoms of depression¹⁴². Furthermore, nicotine administration to rodents produces antidepressant-like effects¹⁴⁹, and several small studies suggest that nicotine may be antidepressant in nonsmokers^{133, 135} in addition to those undergoing smoking cessation. Furthermore, nicotinic partial agonists and antagonists at $\beta 2^*$ and $\alpha 7$ nAChRs, respectively, have antidepressant-like effects in mice^{76, 159, 160}, and one small study reported that varenicline augmentation improved mood in outpatient smokers with persistent depression¹⁶². Yet, it remains unclear whether activation, desensitization, or interference with temporally precise ACh signaling is more important for the antidepressant effects of nicotinic agents¹⁶⁵. More work in humans and animals will be required to dissect the specific nicotinic receptor subtypes and that mediate the effects of ACh on mood, and could lead to the development of novel therapeutics.

The finding that scopolamine exerts a fast-onset and sustained antidepressant effects in humans has led to a renaissance of interest in the cholinergic system as an important factor in the neurochemistry of major depression and bipolar disorder. Controlled studies have indicated that acute i.v. treatment with scopolamine induces fast-onset and sustained antidepressant effects, even in treatment resistant patients with depression^{7, 9–11}. Yet over the last decade, a far greater number of basic and clinical studies have investigated the therapeutic effects and mechanism of action of the NMDA antagonist, ketamine, compared to scopolamine^{124–126}. Since no relative disadvantage of scopolamine regarding efficacy or safety has been reported compared to ketamine, and some common mechanisms of action have been identified, further investigation of the fast-onset antidepressant effects of scopolamine are highly warranted. Possibly, a subpopulation of depressed patients might respond to treatment with scopolamine who do not respond to classical antidepressants, ketamine, or nonpharmacological treatments. Furthermore, a better understanding of the mechanism of action of scopolamine could lead to the development of novel fast-onset antidepressants with improved efficacy and fewer side effects.

The reviewed literature indicates that scopolamine treatment produces rapid-onset antidepressant-like effects in rodents by antagonizing M1-AChRs on somatostatin

interneurons in the mPFC, resulting in disinhibition of pyramidal glutamatergic neurons, a glutamate surge, and ultimately an increase in synapses^{120, 121}. On the other hand, activating M1-AChRs increases depression-like behaviors in humans and animals^{86, 95, 166}. Stimulation of presynaptic M2-AChRs and M4-AChRs decreases acetylcholine release when activated, and hence agonists at these receptors might decrease depressive symptoms by reducing acetylcholine availability⁹⁹. More work is needed to determine a potential role for M3–5-AChRs in the regulation of mood.

Animal studies have suggested that co-treatment with scopolamine and other antidepressants such as venlafaxine or noradrenaline reuptake inhibitors may potentiate antidepressant-like effects^{167, 168}. As discussed above, more selective muscarinic or nicotinic agents such as M1-AChR antagonists, and nicotinic $\alpha 7$ and $\beta 2^*$ agents, also require further investigation as potential therapeutics for the treatment of depression. Both nicotinic and muscarinic receptors also regulate other neurotransmitter systems implicated in mood regulation, including noradrenergic^{169, 170}, serotonergic^{171–173}, dopaminergic^{84, 174}, GABAergic^{175–177}, glutamatergic^{178–180} and cannabinoid¹⁸¹ neurotransmitter systems. Investigation into how the acetylcholine neurotransmitter system interacts with other neurotransmitters, neuromodulators, and epigenetic factors to modulate mood state will be an important direction for future research.

CONCLUSIONS

The catecholaminergic-cholinergic balance hypothesis of depression and mania proposes that a central predominance of acetylcholinergic to catecholaminergic tone underlies depression, while mania results from the converse¹⁵. Evidence to date implicates higher central acetylcholine levels in depression, and antagonism of M1-AChRs by scopolamine in fast-onset antidepressant effects. Blockade of $\alpha 7$ nAChRs receptors and partial agonism of $\beta 2^*$ nAChRs are also implicated in antidepressant-like effects. Future studies are needed to identify optimal pharmacological strategies for treating depression by harnessing the acetylcholinergic system.

Acknowledgements:

S.C.D. was funded by a Rising Star Depression Research Award in Memory of George Largay, R21-MH115395-01, and a NARSAD Independent Investigator Award.

Bibliography

1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA* 2003; 289(23): 3095–3105. [PubMed: 12813115]
2. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. *Arch Gen Psychiatry* 2011; 68(3): 241–251. [PubMed: 21383262]
3. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. *Lancet* 2016; 387(10027): 1561–1572. [PubMed: 26388529]
4. Ashok AH, Marques TR, Jauhar S, Nour MM, Goodwin GM, Young AH et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. *Mol Psychiatry* 2017; 22(5): 666–679. [PubMed: 28289283]

5. Rosenblat JD, McIntyre RS, Alves GS, Fountoulakis KN, Carvalho AF. Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review. *Curr Neuropharmacol* 2015; 13(5): 636–655. [PubMed: 26467412]
6. Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. *Pharmacopsychiatry* 1996; 29(1): 2–11. [PubMed: 8852528]
7. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. *Arch Gen Psychiatry* 2006; 63(10): 1121–1129. [PubMed: 17015814]
8. Furey ML, Drevets WC, Szczepanik J, Khanna A, Nugent A, Zarate CA Jr. Pretreatment Differences in BOLD Response to Emotional Faces Correlate with Antidepressant Response to Scopolamine. *Int J Neuropsychopharmacol* 2015; 18(8).
9. Furey ML, Khanna A, Hoffman EM, Drevets WC. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. *Neuropsychopharmacology* 2010; 35(12): 2479–2488. [PubMed: 20736989]
10. Furey ML, Nugent AC, Speer AM, Luckenbaugh DA, Hoffman EM, Frankel E et al. Baseline mood-state measures as predictors of antidepressant response to scopolamine. *Psychiatry Res* 2012; 196(1): 62–67. [PubMed: 22349648]
11. Ellis JS, Zarate CA Jr., Luckenbaugh DA, Furey ML. Antidepressant treatment history as a predictor of response to scopolamine: clinical implications. *J Affect Disord* 2014; 162: 39–42. [PubMed: 24767003]
12. Rowntree DW, Nevin S, Wilson A. The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis. *J Neurol Neurosurg Psychiatry* 1950; 13(1): 47–62. [PubMed: 15405311]
13. Gershon S, Shaw FH. Psychiatric sequelae of chronic exposure to organophosphorus insecticides. *Lancet* 1961; 1(7191): 1371–1374. [PubMed: 13704751]
14. Bowers MB Jr., Goodman E, Sim VM. Some Behavioral Changes in Man Following Anticholinesterase Administration. *J Nerv Ment Dis* 1964; 138: 383–389. [PubMed: 14141895]
15. Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. *Lancet* 1972; 2(7778): 632–635. [PubMed: 4116781]
16. van Enkhuizen J, Janowsky DS, Olivier B, Minassian A, Perry W, Young JW et al. The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited. *Eur J Pharmacol* 2015; 753: 114–126. [PubMed: 25107282]
17. Potter WZ, Manji HK. Catecholamines in depression: an update. *Clin Chem* 1994; 40(2): 279–287. [PubMed: 8313609]
18. Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. *J Psychopharmacol* 2007; 21(5): 461–471. [PubMed: 17050654]
19. Grossman F, Potter WZ. Catecholamines in depression: a cumulative study of urinary norepinephrine and its major metabolites in unipolar and bipolar depressed patients versus healthy volunteers at the NIMH. *Psychiatry Res* 1999; 87(1): 21–27. [PubMed: 10512151]
20. Domino EF, Olds ME. Cholinergic inhibition of self-stimulation behavior. *J Pharmacol Exp Ther* 1968; 164(1): 202–211. [PubMed: 5722102]
21. Olds ME, Domino EF. Comparison of muscarinic and nicotinic cholinergic agonists on self-stimulation behavior. *J Pharmacol Exp Ther* 1969; 166(2): 189–204. [PubMed: 5813367]
22. Janowsky DS, el-Yousef MK, Davis JM, Hubbard B, Sekerke HJ. Cholinergic reversal of manic symptoms. *Lancet* 1972; 1(7762): 1236–1237.
23. Carroll BJ, Frazer A, Schless A, Mendels J. Cholinergic reversal of manic symptoms. *Lancet* 1973; 1(7800): 427–428.
24. Davis KL, Berger PA, Hollister LE, Defraites E. Physostigmine in mania. *Arch Gen Psychiatry* 1978; 35(1): 119–122. [PubMed: 339869]
25. Janowsky DS, Risch C, Parker D, Huey L, Judd L. Increased vulnerability to cholinergic stimulation in affective-disorder patients [proceedings]. *Psychopharmacol Bull* 1980; 16(4): 29–31.

26. Risch SC, Kalin NH, Janowsky DS. Cholinergic challenges in affective illness: behavioral and neuroendocrine correlates. *J Clin Psychopharmacol* 1981; 1(4): 186–192. [PubMed: 7028800]
27. Risch SC, Cohen RM, Janowsky DS, Kalin NH, Murphy DL. Mood and behavioral effects of physostigmine on humans are accompanied by elevations in plasma beta-endorphin and cortisol. *Science* 1980; 209(4464): 1545–1546. [PubMed: 7433977]
28. Reynolds CF 3rd, Butters MA, Lopez O, Pollock BG, Dew MA, Mulsant BH et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. *Arch Gen Psychiatry* 2011; 68(1): 51–60. [PubMed: 21199965]
29. Katona C. Dementia: Does depression predict donepezil response in MCI? *Nat Rev Neurol* 2009; 5(11): 585–586. [PubMed: 19888316]
30. Altinyazar V, Sirin FB, Sutcu R, Eren I, Omurlu IK. The Red Blood Cell Acetylcholinesterase Levels of Depressive Patients with Suicidal Behavior in an Agricultural Area. *Indian J Clin Biochem* 2016; 31(4): 473–479. [PubMed: 27605747]
31. Saricicek A, Esterlis I, Maloney KH, Mineur YS, Ruf BM, Muralidharan A et al. Persistent beta2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. *Am J Psychiatry* 2012; 169(8): 851–859. [PubMed: 22772158]
32. Tamminga C, Smith RC, Chang S, Haraszti JS, Davis JM. Depression Associated with Oral Choline. *Lancet* 1976; 2(7991): 905–905.
33. Growdon JH, Hirsch MJ, Wurtman RJ, Wiener W. Oral Choline Administration to Patients with Tardive-Dyskinesia. *New Engl J Med* 1977; 297(10): 524–527. [PubMed: 887103]
34. DE C. Affective changes with deanol In: Davis KL B P (ed). *Brain acetylcholine and neuropsychiatric disease*. Plenum Press: New York, 1979.
35. Brown ES, Gabrielson B. A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. *J Affect Disord* 2012; 143(1–3): 257–260. [PubMed: 22974472]
36. Castagna A, Cotroneo AM, Ruotolo G, Gareri P. The CITIRIVAD Study: CITIcoline plus RIVAstigmine in Elderly Patients Affected with Dementia Study. *Clin Drug Investig* 2016; 36(12): 1059–1065.
37. Gareri P, Castagna A, Cotroneo AM, Putignano D, Conforti R, Santamaria F et al. The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer’s Disease Study. *J Alzheimers Dis* 2017; 56(2): 557–565. [PubMed: 28035929]
38. Roohi-Azizi M, Arabzadeh S, Amidfar M, Salimi S, Zarindast MR, Talaei A et al. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. *Clin Neuropharmacol* 2017; 40(1): 1–5. [PubMed: 28085707]
39. Yerevanian BI, Woolf PD, Iker HP. Plasma ACTH levels in depression before and after recovery: relationship to the dexamethasone suppression test. *Psychiatry Res* 1983; 10(3): 175–181. [PubMed: 6320245]
40. Young EA, Ribeiro SC. Sex differences in the ACTH response to 24H metyrapone in depression. *Brain Res* 2006; 1126(1): 148–155. [PubMed: 16824495]
41. Carroll BJ, Cassidy F, Naftolowitz D, Tatham NE, Wilson WH, Iranmanesh A et al. Pathophysiology of hypercortisolism in depression. *Acta Psychiatr Scand Suppl* 2007; (433): 90–103. [PubMed: 17280575]
42. Axelson DA, Doraiswamy PM, McDonald WM, Boyko OB, Tupler LA, Patterson LJ et al. Hypercortisolemia and hippocampal changes in depression. *Psychiatry Res* 1993; 47(2): 163–173. [PubMed: 8341769]
43. Bremner MA, Deeg DJ, Beekman AT, Penninx BW, Lips P, Hoogendijk WJ. Major depression in late life is associated with both hypo- and hypercortisolemia. *Biol Psychiatry* 2007; 62(5): 479–486. [PubMed: 17481591]
44. Risch SC. beta-Endorphin hypersecretion in depression: possible cholinergic mechanisms. *Biol Psychiatry* 1982; 17(10): 1071–1079. [PubMed: 6293594]
45. Hegadoren KM, O’Donnell T, Lanius R, Coupland NJ, Lacaze-Masmonteil N. The role of beta-endorphin in the pathophysiology of major depression. *Neuropeptides* 2009; 43(5): 341–353. [PubMed: 19647870]

46. Goodwin GM, Austin MP, Curran SM, Ross M, Murray C, Prentice N et al. The elevation of plasma beta-endorphin levels in major depression. *J Affect Disord* 1993; 29(4): 281–289. [PubMed: 8126314]
47. Rubin RT, Rhodes ME, Miller TH, Jakab RL, Czambel RK. Sequence of pituitary-adrenal cortical hormone responses to low-dose physostigmine administration in young adult women and men. *Life Sci* 2006; 79(24): 2260–2268. [PubMed: 16935309]
48. Peskind ER, Raskind MA, Wingerson D, Pascualy M, Thal LJ, Dobie DJ et al. Enhanced hypothalamic-pituitary-adrenocortical axis responses to physostigmine in normal aging. *J Gerontol A Biol Sci Med Sci* 1995; 50(2): M114–120. [PubMed: 7874590]
49. Risch SC, Janowsky DS, Gillin JC. Muscarinic supersensitivity of anterior pituitary ACTH and B-endorphin release in major depressive illness. *Peptides* 1983; 4(5): 789–792. [PubMed: 6318208]
50. Doerr P, Berger M. Physostigmine-induced escape from dexamethasone suppression in normal adults. *Biol Psychiatry* 1983; 18(2): 261–268. [PubMed: 6830935]
51. Rubin RT, O'Toole SM, Rhodes ME, Sekula LK, Czambel RK. Hypothalamo-pituitary-adrenal cortical responses to low-dose physostigmine and arginine vasopressin administration: sex differences between major depressives and matched control subjects. *Psychiatry Res* 1999; 89(1): 1–20. [PubMed: 10643873]
52. Modell S, Lauer CJ. Rapid eye movement (REM) sleep: an endophenotype for depression. *Curr Psychiatry Rep* 2007; 9(6): 480–485. [PubMed: 18221628]
53. Palagini L, Baglioni C, Ciapparelli A, Gemignani A, Riemann D. REM sleep dysregulation in depression: state of the art. *Sleep Med Rev* 2013; 17(5): 377–390. [PubMed: 23391633]
54. Modell S, Ising M, Holsboer F, Lauer CJ. The Munich vulnerability study on affective disorders: premonitory polysomnographic profile of affected high-risk probands. *Biol Psychiatry* 2005; 58(9): 694–699. [PubMed: 16018976]
55. Giles DE, Kupfer DJ, Roffwarg HP, Rush AJ, Biggs MM, Etzel BA. Polysomnographic parameters in first-degree relatives of unipolar probands. *Psychiatry Res* 1989; 27(2): 127–136. [PubMed: 2710861]
56. Sitaram N, Nurnberger JI Jr., Gershon ES, Gillin JC. Faster cholinergic REM sleep induction in euthymic patients with primary affective illness. *Science* 1980; 208(4440): 200–202. [PubMed: 7361118]
57. Biard K, Douglass AB, De Koninck J. The effects of galantamine and buspirone on sleep structure: Implications for understanding sleep abnormalities in major depression. *J Psychopharmacol* 2015; 29(10): 1106–1111. [PubMed: 26259773]
58. Gillin JC, Sitaram N, Mendelson WB, Wyatt RJ. Physostigmine alters onset but not duration of REM sleep in man. *Psychopharmacology (Berl)* 1978; 58(1): 111–114. [PubMed: 209490]
59. Schredl M, Weber B, Leins ML, Heuser I. Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons. *Exp Gerontol* 2001; 36(2): 353–361. [PubMed: 11226748]
60. Gillin JC, Sutton L, Ruiz C, Kelsoe J, Dupont RM, Darko D et al. The cholinergic rapid eye movement induction test with arecoline in depression. *Arch Gen Psychiatry* 1991; 48(3): 264–270. [PubMed: 1996921]
61. Sitaram N, Gillin JC. Development and use of pharmacological probes of the CNS in man: evidence of cholinergic abnormality in primary affective illness. *Biol Psychiatry* 1980; 15(6): 925–955. [PubMed: 7459412]
62. Sitaram N, Nurnberger JI Jr., Gershon ES, Gillin JC. Cholinergic regulation of mood and REM sleep: potential model and marker of vulnerability to affective disorder. *Am J Psychiatry* 1982; 139(5): 571–576. [PubMed: 7072840]
63. Sitaram N, Dube S, Keshavan M, Davies A, Reynal P. The association of supersensitive cholinergic REM-induction and affective illness within pedigrees. *J Psychiatr Res* 1987; 21(4): 487–497. [PubMed: 3440958]
64. Lauriello J, Kenny WM, Sutton L, Golshan S, Ruiz C, Kelsoe J et al. The cholinergic REM sleep induction test with pilocarpine in mildly depressed patients and normal controls. *Biol Psychiatry* 1993; 33(1): 33–39. [PubMed: 8420594]

65. Berkowitz A, Sutton L, Janowsky DS, Gillin JC. Pilocarpine, an orally active muscarinic cholinergic agonist, induces REM sleep and reduces delta sleep in normal volunteers. *Psychiatry Res* 1990; 33(2): 113–119. [PubMed: 2243887]
66. Lauer CJ, Modell S, Schreiber W, Krieg JC, Holsboer F. Prediction of the development of a first major depressive episode with a rapid eye movement sleep induction test using the cholinergic agonist RS 86. *J Clin Psychopharmacol* 2004; 24(3): 356–357. [PubMed: 15118498]
67. Perlis ML, Smith MT, Orff HJ, Andrews PJ, Gillin JC, Giles DE. The effects of an orally administered cholinergic agonist on REM sleep in major depression. *Biol Psychiatry* 2002; 51(6): 457–462. [PubMed: 11922879]
68. Nurnberger J Jr., Sitaram N, Gershon ES, Gillin JC. A twin study of cholinergic REM induction. *Biol Psychiatry* 1983; 18(10): 1161–1165. [PubMed: 6652156]
69. Kim EJ, Jeong DU. Transdermal scopolamine alters phasic REM activity in normal young adults. *Sleep* 1999; 22(4): 515–520. [PubMed: 10389227]
70. Rao U, Lutchmansingh P, Poland RE. Age-related effects of scopolamine on REM sleep regulation in normal control subjects: relationship to sleep abnormalities in depression. *Neuropsychopharmacology* 1999; 21(6): 723–730. [PubMed: 10633478]
71. Poland RE, McCracken JT, Lutchmansingh P, Lesser IM, Tondo L, Edwards C et al. Differential response of rapid eye movement sleep to cholinergic blockade by scopolamine in currently depressed, remitted, and normal control subjects. *Biol Psychiatry* 1997; 41(9): 929–938. [PubMed: 9110098]
72. Sokolski KN, Demet EM. Increased pupillary sensitivity to pilocarpine in depression. *Prog Neuropsychopharmacol Biol Psychiatry* 1996; 20(2): 253–262. [PubMed: 8861191]
73. Sokolski KN, DeMet EM. Cholinergic sensitivity predicts severity of mania. *Psychiatry Res* 2000; 95(3): 195–200. [PubMed: 10974358]
74. Mineur YS, Obayemi A, Wigstrand MB, Fote GM, Calarco CA, Li AM et al. Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior. *Proc Natl Acad Sci U S A* 2013; 110(9): 3573–3578. [PubMed: 23401542]
75. Addy NA, Nunes EJ, Wickham RJ. Ventral tegmental area cholinergic mechanisms mediate behavioral responses in the forced swim test. *Behav Brain Res* 2015; 288: 54–62. [PubMed: 25865152]
76. Mineur YS, Mose TN, Blakeman S, Picciotto MR. Hippocampal alpha7 nicotinic ACh receptors contribute to modulation of depression-like behaviour in C57BL/6J mice. *Br J Pharmacol* 2017.
77. Mineur YS, Bentham MP, Zhou WL, Plantenga ME, McKee SA, Picciotto MR. Antidepressant-like effects of guanfacine and sex-specific differences in effects on c-fos immunoreactivity and paired-pulse ratio in male and female mice. *Psychopharmacology (Berl)* 2015; 232(19): 3539–3549. [PubMed: 26146014]
78. van Enkhuizen J, Milienne-Petiot M, Geyer MA, Young JW. Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most, but not all features. *Psychopharmacology (Berl)* 2015; 232(18): 3455–3467. [PubMed: 26141192]
79. Druhan JP, Fibiger HC, Phillips AG. Differential effects of cholinergic drugs on discriminative cues and self-stimulation produced by electrical stimulation of the ventral tegmental area. *Psychopharmacology (Berl)* 1989; 97(3): 331–338. [PubMed: 2497481]
80. Dori A, Soreq H. ARP, the cleavable C-terminal peptide of “readthrough” acetylcholinesterase, promotes neuronal development and plasticity. *J Mol Neurosci* 2006; 28(3): 247–255. [PubMed: 16691012]
81. Kaufer D, Friedman A, Seidman S, Soreq H. Anticholinesterases induce multigenic transcriptional feedback response suppressing cholinergic neurotransmission. *Chem Biol Interact* 1999; 119–120: 349–360.
82. Shaked I, Zimmerman G, Soreq H. Stress-induced alternative splicing modulations in brain and periphery: acetylcholinesterase as a case study. *Ann N Y Acad Sci* 2008; 1148: 269–281. [PubMed: 19120119]
83. Nijholt I, Farchi N, Kye M, Sklan EH, Shoham S, Verbeure B et al. Stress-induced alternative splicing of acetylcholinesterase results in enhanced fear memory and long-term potentiation. *Mol Psychiatry* 2004; 9(2): 174–183. [PubMed: 14581933]

84. Small KM, Nunes E, Hughley S, Addy NA. Ventral tegmental area muscarinic receptors modulate depression and anxiety-related behaviors in rats. *Neurosci Lett* 2016; 616: 80–85. [PubMed: 26828299]
85. Chau DT, Rada PV, Kim K, Kosloff RA, Hoebel BG. Fluoxetine alleviates behavioral depression while decreasing acetylcholine release in the nucleus accumbens shell. *Neuropsychopharmacology* 2011; 36(8): 1729–1737. [PubMed: 21525864]
86. Chau DT, Rada P, Kosloff RA, Taylor JL, Hoebel BG. Nucleus accumbens muscarinic receptors in the control of behavioral depression: antidepressant-like effects of local M1 antagonist in the Porsolt swim test. *Neuroscience* 2001; 104(3): 791–798. [PubMed: 11440810]
87. Taylor KM, Mark GP, Hoebel BG. Conditioned taste aversion from neostigmine or methyl-naloxonium in the nucleus accumbens. *Physiol Behav* 2011; 104(1): 82–86. [PubMed: 21549734]
88. Chau D, Rada PV, Kosloff RA, Hoebel BG. Cholinergic, M1 receptors in the nucleus accumbens mediate behavioral depression. A possible downstream target for fluoxetine. *Ann N Y Acad Sci* 1999; 877: 769–774. [PubMed: 10415702]
89. Warner-Schmidt JL, Schmidt EF, Marshall JJ, Rubin AJ, Arango-Lievano M, Kaplitt MG et al. Cholinergic interneurons in the nucleus accumbens regulate depression-like behavior. *Proc Natl Acad Sci U S A* 2012; 109(28): 11360–11365. [PubMed: 22733786]
90. El-Yousef MK, Janowsky DS, Davis JM, Rosenblatt JE. Induction of severe depression by physostigmine in marijuana intoxicated individuals. *Br J Addict Alcohol Other Drugs* 1973; 68(4): 321–325. [PubMed: 4528602]
91. Janowsky DS, Risch SC, Kennedy B, Ziegler M, Huey L. Central muscarinic effects of physostigmine on mood, cardiovascular function, pituitary and adrenal neuroendocrine release. *Psychopharmacology (Berl)* 1986; 89(2): 150–154. [PubMed: 3088629]
92. Nurnberger JI Jr., Jimerson DC, Simmons-Alling S, Tamminga C, Nadi NS, Lawrence D et al. Behavioral, physiological, and neuroendocrine responses to arecoline in normal twins and “well state” bipolar patients. *Psychiatry Res* 1983; 9(3): 191–200. [PubMed: 6312479]
93. Sunderland T, Tariot PN, Newhouse PA. Differential responsiveness of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. *Brain Res* 1988; 472(4): 371–389. [PubMed: 3066441]
94. Davis KL, Hollander E, Davidson M, Davis BM, Mohs RC, Horvath TB. Induction of depression with oxotremorine in patients with Alzheimer’s disease. *Am J Psychiatry* 1987; 144(4): 468–471. [PubMed: 3565616]
95. Krieg JC, Berger M. Treatment of mania with the cholinomimetic agent RS 86. *Br J Psychiatry* 1986; 148: 613.
96. Janowsky DS, el-Yousef MK, Davis JM. Acetylcholine and depression. *Psychosom Med* 1974; 36(3): 248–257. [PubMed: 4829619]
97. Janowsky DS, Risch SC, Kennedy B, Ziegler MG, Huey LY. Acute effects of physostigmine and neostigmine in man. *Mil Med* 1986; 151(1): 48–51. [PubMed: 3080707]
98. Dohanich GP, Johnson AE, Nock B, McEwen BS, Feder HH. Distribution of cholinergic muscarinic binding sites in guinea-pig brain as determined by in vitro autoradiography of [3H]N-methyl scopolamine binding. *Eur J Pharmacol* 1985; 119(1–2): 9–16. [PubMed: 4085563]
99. Iannazzo L, Majewski H. M(2)/M(4)-muscarinic receptors mediate automodulation of acetylcholine outflow from mouse cortex. *Neurosci Lett* 2000; 287(2): 129–132. [PubMed: 10854729]
100. Cannon DM, Carson RE, Nugent AC, Eckelman WC, Kiesewetter DO, Williams J et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. *Arch Gen Psychiatry* 2006; 63(7): 741–747. [PubMed: 16818863]
101. Charles HC, Lazeyras F, Krishnan KR, Boyko OB, Payne M, Moore D. Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy. *Prog Neuropsychopharmacol Biol Psychiatry* 1994; 18(7): 1121–1127. [PubMed: 7846284]
102. MacMaster FP, Kusumakar V. Choline in pediatric depression. *Mcgill J Med* 2006; 9(1): 24–27. [PubMed: 19529805]

103. Gibbons AS, Scarr E, McLean C, Sundram S, Dean B. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. *J Affect Disord* 2009; 116(3): 184–191. [PubMed: 19103464]
104. Zavitsanou K, Katsifis A, Yu Y, Huang XF. M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. *Brain Res Bull* 2005; 65(5): 397–403. [PubMed: 15833594]
105. Zavitsanou K, Katsifis A, Mattner F, Huang XF. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. *Neuropsychopharmacology* 2004; 29(3): 619–625. [PubMed: 14694353]
106. Jeon WJ, Gibbons AS, Dean B. The use of a modified [3H]4-DAMP radioligand binding assay with increased selectivity for muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders. *Prog Neuropsychopharmacol Biol Psychiatry* 2013; 47: 7–12. [PubMed: 23962466]
107. Milaneschi Y, Lamers F, Peyrot WJ, Abdellaoui A, Willemsen G, Hottenga JJ et al. Polygenic dissection of major depression clinical heterogeneity. *Mol Psychiatry* 2016; 21(4): 516–522. [PubMed: 26122587]
108. Peterson RE, Cai N, Dahl AW, Bigdeli TB, Edwards AC, Webb BT et al. Molecular Genetic Analysis Subdivided by Adversity Exposure Suggests Etiologic Heterogeneity in Major Depression. *Am J Psychiatry* 2018: appiajp201717060621.
109. Janowsky DS, Risch SC, Gillin JC. Adrenergic-cholinergic balance and the treatment of affective disorders. *Prog Neuropsychopharmacol Biol Psychiatry* 1983; 7(2–3): 297–307. [PubMed: 6684317]
110. Janowsky DS, Overstreet DH, Nurnberger JI Jr. Is cholinergic sensitivity a genetic marker for the affective disorders? *Am J Med Genet* 1994; 54(4): 335–344. [PubMed: 7726206]
111. Coid J, Strang J. Mania secondary to procyclidine (“Kemadrin”) abuse. *Br J Psychiatry* 1982; 141: 81–84. [PubMed: 7116076]
112. Smith JM. Abuse of the antiparkinson drugs: a review of the literature. *J Clin Psychiatry* 1980; 41(10): 351–354. [PubMed: 7430078]
113. Jellinek T, Gardos G, Cole JO. Adverse effects of antiparkinson drug withdrawal. *Am J Psychiatry* 1981; 138(12): 1567–1571. [PubMed: 6118066]
114. Newhouse PA, Sunderland T, Tariot PN, Weingartner H, Thompson K, Mellow AM et al. The effects of acute scopolamine in geriatric depression. *Arch Gen Psychiatry* 1988; 45(10): 906–912. [PubMed: 3048225]
115. Gillin JC, Lauriello J, Kelsoe JR, Rapaport M, Golshan S, Kenny WM et al. No antidepressant effect of biperiden compared with placebo in depression: a double-blind 6-week clinical trial. *Psychiatry Res* 1995; 58(2): 99–105. [PubMed: 8570773]
116. Gillin JC, Sutton L, Ruiz C, Darko D, Golshan S, Risch SC et al. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group. *Biol Psychiatry* 1991; 30(2): 157–169. [PubMed: 1655072]
117. Khajavi D, Farokhnia M, Modabbernia A, Ashrafi M, Abbasi SH, Tabrizi M et al. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2012; 73(11): 1428–1433. [PubMed: 23146150]
118. Ghosal S, Bang E, Yue W, Hare BD, Lepack AE, Girgenti MJ et al. Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine. *Biol Psychiatry* 2017.
119. Navarria A, Wohleb ES, Voleti B, Ota KT, Duthel S, Lepack AE et al. Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. *Neurobiol Dis* 2015; 82: 254–261. [PubMed: 26102021]
120. Wohleb ES, Wu M, Gerhard DM, Taylor SR, Picciotto MR, Alreja M et al. GABA interneurons mediate the rapid antidepressant-like effects of scopolamine. *J Clin Invest* 2016; 126(7): 2482–2494. [PubMed: 27270172]

121. Voleti B, Navarria A, Liu RJ, Banasr M, Li N, Terwilliger R et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. *Biol Psychiatry* 2013; 74(10): 742–749. [PubMed: 23751205]
122. Geoffroy M, Scheel-Kruger J, Christensen AV. Effect of imipramine in the “learned helplessness” model of depression in rats is not mimicked by combinations of specific reuptake inhibitors and scopolamine. *Psychopharmacology (Berl)* 1990; 101(3): 371–375. [PubMed: 2141946]
123. Ramaker MJ, Dulawa SC. Identifying fast-onset antidepressants using rodent models. *Mol Psychiatry* 2017.
124. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. *Nature* 2011; 475(7354): 91–95. [PubMed: 21677641]
125. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. *Nature* 2016; 533(7604): 481–486. [PubMed: 27144355]
126. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. *Science* 2010; 329(5994): 959–964. [PubMed: 20724638]
127. Witkin JM, Overshiner C, Li X, Catlow JT, Wishart GN, Schober DA et al. M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. *J Pharmacol Exp Ther* 2014; 351(2): 448–456. [PubMed: 25187432]
128. Hughes JR. Tobacco withdrawal in self-quitters. *J Consult Clin Psychol* 1992; 60(5): 689–697. [PubMed: 1401384]
129. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW. Symptoms of tobacco withdrawal. A replication and extension. *Arch Gen Psychiatry* 1991; 48(1): 52–59. [PubMed: 1984762]
130. Covey LS, Glassman AH, Stetner F. Depression and depressive symptoms in smoking cessation. *Compr Psychiatry* 1990; 31(4): 350–354. [PubMed: 2387147]
131. Covey LS, Glassman AH, Stetner F. Major depression following smoking cessation. *Am J Psychiatry* 1997; 154(2): 263–265. [PubMed: 9016279]
132. Shiffman S, Ferguson SG, Gwaltney CJ, Balabanis MH, Shadel WG. Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. *Psychopharmacology (Berl)* 2006; 184(3–4): 637–644. [PubMed: 16261317]
133. McCleron FJ, Hiott FB, Westman EC, Rose JE, Levin ED. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. *Psychopharmacology (Berl)* 2006; 189(1): 125–133. [PubMed: 16977477]
134. Salin-Pascual RJ, Rosas M, Jimenez-Genchi A, Rivera-Meza BL, Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. *J Clin Psychiatry* 1996; 57(9): 387–389. [PubMed: 9746444]
135. Salin-Pascual RJ, de la Fuente JR, Galicia-Polo L, Drucker-Colin R. Effects of transdermal nicotine on mood and sleep in nonsmoking major depressed patients. *Psychopharmacology (Berl)* 1995; 121(4): 476–479. [PubMed: 8619011]
136. Markou A, Kosten TR, Koob GF. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. *Neuropsychopharmacology* 1998; 18(3): 135–174. [PubMed: 9471114]
137. Fava M, Ramey T, Pickering E, Kinrys G, Boyer S, Altstiel L. A randomized, double-blind, placebo-controlled phase 2 study of the augmentation of a nicotinic acetylcholine receptor partial agonist in depression: is there a relationship to leptin levels? *J Clin Psychopharmacol* 2015; 35(1): 51–56. [PubMed: 25422883]
138. Wang HR, Woo YS, Bahk WM. Ineffectiveness of nicotinic acetylcholine receptor antagonists for treatment-resistant depression: a meta-analysis. *Int Clin Psychopharmacol* 2016; 31(5): 241–248. [PubMed: 26982579]
139. Moller HJ, Demyttenaere K, Olausson B, Szamosi J, Wilson E, Hosford D et al. Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to

- prior antidepressant therapy. *World J Biol Psychiatry* 2015; 16(7): 483–501. [PubMed: 25602163]
140. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR. Nicotinic acetylcholine receptors as targets for antidepressants. *Mol Psychiatry* 2002; 7(6): 525–535. [PubMed: 12140772]
141. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. *J Pharmacol Exp Ther* 2000; 295(1): 321–327. [PubMed: 10991997]
142. Kenny PJ, Markou A. Neurobiology of the nicotine withdrawal syndrome. *Pharmacol Biochem Behav* 2001; 70(4): 531–549. [PubMed: 11796152]
143. Frahm S, Slimak MA, Ferrarese L, Santos-Torres J, Antolin-Fontes B, Auer S et al. Aversion to nicotine is regulated by the balanced activity of beta4 and alpha5 nicotinic receptor subunits in the medial habenula. *Neuron* 2011; 70(3): 522–535. [PubMed: 21555077]
144. Salas R, Pieri F, De Biasi M. Decreased signs of nicotine withdrawal in mice null for the beta4 nicotinic acetylcholine receptor subunit. *J Neurosci* 2004; 24(45): 10035–10039. [PubMed: 15537871]
145. Salas R, Orr-Urtreger A, Broide RS, Beaudet A, Paylor R, De Biasi M. The nicotinic acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in vivo. *Mol Pharmacol* 2003; 63(5): 1059–1066. [PubMed: 12695534]
146. Upton M, Lotfipour S. alpha2-Null mutant mice have altered levels of neuronal activity in restricted midbrain and limbic brain regions during nicotine withdrawal as demonstrated by cfos expression. *Biochem Pharmacol* 2015; 97(4): 558–565. [PubMed: 26111579]
147. Kenny PJ, Markou A. Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. *Neuropsychopharmacology* 2006; 31(6): 1203–1211. [PubMed: 16192981]
148. Andreasen JT, Redrobe JP. Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests. *Behav Brain Res* 2009; 197(1): 150–156. [PubMed: 18786574]
149. Andreasen JT, Henningsen K, Bate S, Christiansen S, Wiborg O. Nicotine reverses anhedonic-like response and cognitive impairment in the rat chronic mild stress model of depression: comparison with sertraline. *J Psychopharmacol* 2011; 25(8): 1134–1141. [PubMed: 21169388]
150. Esterlis I, Hannestad JO, Bois F, Sewell RA, Tyndale RF, Seibyl JP et al. Imaging changes in synaptic acetylcholine availability in living human subjects. *J Nucl Med* 2013; 54(1): 78–82. [PubMed: 23160789]
151. Hannestad JO, Cosgrove KP, DellaGioia NF, Perkins E, Bois F, Bhagwagar Z et al. Changes in the cholinergic system between bipolar depression and euthymia as measured with [123I]5IA single photon emission computed tomography. *Biol Psychiatry* 2013; 74(10): 768–776. [PubMed: 23773793]
152. Villegier AS, Gallager B, Heston J, Belluzzi JD, Leslie FM. Age influences the effects of nicotine and monoamine oxidase inhibition on mood-related behaviors in rats. *Psychopharmacology (Berl)* 2010; 208(4): 593–601. [PubMed: 20069419]
153. Tizabi Y, Overstreet DH, Rezvani AH, Louis VA, Clark E Jr., Janowsky DS et al. Antidepressant effects of nicotine in an animal model of depression. *Psychopharmacology (Berl)* 1999; 142(2): 193–199. [PubMed: 10102772]
154. Haj-Mirzaian A, Kordjazy N, Haj-Mirzaian A, Ostadhadi S, Ghasemi M, Amiri S et al. Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests. *Psychopharmacology (Berl)* 2015; 232(19): 3551–3561. [PubMed: 26173610]
155. Vieyra-Reyes P, Mineur YS, Picciotto MR, Tunes I, Vidaltamayo R, Drucker-Colin R. Antidepressant-like effects of nicotine and transcranial magnetic stimulation in the olfactory bulbectomy rat model of depression. *Brain Res Bull* 2008; 77(1): 13–18. [PubMed: 18582540]
156. Andreasen JT, Redrobe JP. Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests: role of strain, test and sex. *Behav Pharmacol* 2009; 20(3): 286–295. [PubMed: 19404193]

157. Andreasen JT, Olsen GM, Wiborg O, Redrobe JP. Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. *J Psychopharmacol* 2009; 23(7): 797–804. [PubMed: 18583432]
158. Aboul-Fotouh S. Behavioral effects of nicotinic antagonist mecamylamine in a rat model of depression: prefrontal cortex level of BDNF protein and monoaminergic neurotransmitters. *Psychopharmacology (Berl)* 2015; 232(6): 1095–1105. [PubMed: 25315361]
159. Mineur YS, Fote GM, Blakeman S, Cahuzac EL, Newbold SA, Picciotto MR. Multiple Nicotinic Acetylcholine Receptor Subtypes in the Mouse Amygdala Regulate Affective Behaviors and Response to Social Stress. *Neuropsychopharmacology* 2016; 41(6): 1579–1587. [PubMed: 26471256]
160. Rollema H, Guanowsky V, Mineur YS, Shrikhande A, Coe JW, Seymour PA et al. Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. *Eur J Pharmacol* 2009; 605(1–3): 114–116. [PubMed: 19168054]
161. Reperant C, Pons S, Dufour E, Rollema H, Gardier AM, Maskos U. Effect of the alpha4beta2* nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knock-out mice with selective re-expression of the beta2 subunit in the ventral tegmental area. *Neuropharmacology* 2010; 58(2): 346–350. [PubMed: 19887076]
162. Philip NS, Carpenter LL, Tyrka AR, Whiteley LB, Price LH. Varenicline augmentation in depressed smokers: an 8-week, open-label study. *J Clin Psychiatry* 2009; 70(7): 1026–1031. [PubMed: 19323966]
163. Mineur YS, Einstein EB, Seymour PA, Coe JW, O'Neill BT, Rollema H et al. alpha 4 beta 2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties. *Behavioural Pharmacology* 2011; 22(4): 291–299. [PubMed: 21566524]
164. Mineur YS, Cahuzac EL, Mose TN, Bentham MP, Plantenga ME, Thompson DC et al. Interaction between noradrenergic and cholinergic signaling in amygdala regulates anxiety- and depression-related behaviors in mice. *Neuropsychopharmacology* 2018.
165. Ballinger EC, Ananth M, Talmage DA, Role LW. Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. *Neuron* 2016; 91(6): 1199–1218. [PubMed: 27657448]
166. Rada P, Colasante C, Skirzewski M, Hernandez L, Hoebel B. Behavioral depression in the swim test causes a biphasic, long-lasting change in accumbens acetylcholine release, with partial compensation by acetylcholinesterase and muscarinic-1 receptors. *Neuroscience* 2006; 141(1): 67–76. [PubMed: 16677771]
167. Singh P, Singh TG. Modulation of muscarinic system with serotonin-norepinephrine reuptake inhibitor antidepressant attenuates depression in mice. *Indian J Pharmacol* 2015; 47(4): 388–393. [PubMed: 26288470]
168. Palucha-Poniewiera A, Podkowa K, Lenda T, Pilc A. The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test. *Prog Neuropsychopharmacol Biol Psychiatry* 2017; 79(Pt B): 155–161. [PubMed: 28647535]
169. Beiranvand F, Zlabinger C, Orr-Urtreger A, Ristl R, Huck S, Scholze P. Nicotinic acetylcholine receptors control acetylcholine and noradrenaline release in the rodent habenulo-interpeduncular complex. *Br J Pharmacol* 2014; 171(23): 5209–5224. [PubMed: 25041479]
170. Barik J, Wonnacott S. Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal. *Mol Pharmacol* 2006; 69(2): 618–628. [PubMed: 16269536]
171. Kenny PJ, File SE, Neal MJ. Evidence for a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release. *J Neurochem* 2000; 75(6): 2409–2414. [PubMed: 11080192]
172. Dougherty JJ, Nichols RA. Cross-regulation between colocalized nicotinic acetylcholine and 5-HT3 serotonin receptors on presynaptic nerve terminals. *Acta Pharmacol Sin* 2009; 30(6): 788–794. [PubMed: 19498419]
173. Schwartz RD, Lehmann J, Kellar KJ. Presynaptic nicotinic cholinergic receptors labeled by [3H]acetylcholine on catecholamine and serotonin axons in brain. *J Neurochem* 1984; 42(5): 1495–1498. [PubMed: 6707650]

174. Sharples CG, Kaiser S, Soliakov L, Marks MJ, Collins AC, Washburn M et al. UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes. *J Neurosci* 2000; 20(8): 2783–2791. [PubMed: 10751429]
175. Maggi L, Sher E, Cherubini E. Regulation of GABA release by nicotinic acetylcholine receptors in the neonatal rat hippocampus. *J Physiol* 2001; 536(Pt 1): 89–100. [PubMed: 11579159]
176. Aracri P, Consonni S, Morini R, Perrella M, Rodighiero S, Amadeo A et al. Tonic modulation of GABA release by nicotinic acetylcholine receptors in layer V of the murine prefrontal cortex. *Cereb Cortex* 2010; 20(7): 1539–1555. [PubMed: 19812239]
177. Li DP, Pan YZ, Pan HL. Acetylcholine attenuates synaptic GABA release to supraoptic neurons through presynaptic nicotinic receptors. *Brain Res* 2001; 920(1–2): 151–158. [PubMed: 11716821]
178. Garduno J, Galindo-Charles L, Jimenez-Rodriguez J, Galarraga E, Tapia D, Mihailescu S et al. Presynaptic alpha4beta2 nicotinic acetylcholine receptors increase glutamate release and serotonin neuron excitability in the dorsal raphe nucleus. *J Neurosci* 2012; 32(43): 15148–15157. [PubMed: 23100436]
179. Bortz DM, Mikkelsen JD, Bruno JP. Localized infusions of the partial alpha 7 nicotinic receptor agonist SSR180711 evoke rapid and transient increases in prefrontal glutamate release. *Neuroscience* 2013; 255: 55–67. [PubMed: 24095692]
180. Reno LA, Zago W, Markus RP. Release of [(3)H]-L-glutamate by stimulation of nicotinic acetylcholine receptors in rat cerebellar slices. *Neuroscience* 2004; 124(3): 647–653. [PubMed: 14980735]
181. Kim J, Isokawa M, Ledent C, Alger BE. Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. *J Neurosci* 2002; 22(23): 10182–10191. [PubMed: 12451119]
182. Risch SC, Siever LJ, Gillin JC, Janowsky DS, Sitaram N, Weker J et al. Differential Mood Effects of Arecoline in Depressed-Patients and Normal Volunteers. *Psychopharmacology Bulletin* 1983; 19(4): 696–698.
183. Casey DE. Mood alterations during deanol therapy. *Psychopharmacology (Berl)* 1979; 62(2): 187–191. [PubMed: 111283]

Box 1

Future research directions

1. Further explore potential antidepressant effects of nAChR agents in humans and animals.
2. Further elucidate the similarities and differences in the mechanisms of antidepressant action of scopolamine versus ketamine using animal models.
3. Longitudinal imaging studies assessing M2-AChR receptor expression during illness and remission.
4. Further elucidate the mechanism of action of scopolamine to identify novel targets for antidepressant development.
5. Identify biomarkers that identify responders to scopolamine versus ketamine treatment.
6. Replicate oral and i.v. trials of scopolamine in affective disorder patients.
7. Use human imaging studies and animal models to identify the neural circuits involved in scopolamine's fast-onset antidepressant effects.

Abbreviations: M2-AChR, muscarinic 2 acetylcholine receptor.




Figure 1. Acetylcholine synthesis and degradation, and the actions of pharmacological interventions. Acetylcholine (ACh) is synthesized in neurons from choline and acetyl-coenzyme A by the enzyme acetyltransferase. ACh is protected from degradation by packaging within synaptic vesicles. ACh is released into the synaptic cleft where it acts upon pre- and postsynaptic muscarinic and nicotinic receptors, and degraded into choline and acetate by the enzyme acetylcholinesterase (AChE). Choline is recycled back into neurons. AChE inhibitors (AChEIs) such as physostigmine and donepezil prevent the breakdown of ACh. Precursors such as deanol and choline contribute to ACh synthesis. Abbreviations: AcCoA, acetyl coenzyme A; AChR, acetylcholine receptor.




Figure 2. Sites of action of scopolamine's rapid antidepressant-like effects within cholinergic circuitry. Rodent studies have shown that acute scopolamine treatment can induce fast-onset antidepressant effects when administered within the mPFC, nAC, and VTA (shown in yellow). Cholinergic innervation of the mPFC and VTA is supplied by the basal forebrain and brainstem cholinergic systems, respectively. The only source of acetylcholine within the nAC comes from local cholinergic interneurons (shown in red). Abbreviations: nAC, nucleus accumbens; mPFC, medial prefrontal cortex; VTA, ventral tegmental area; MS, medial septal nucleus; vDB, vertical diagonal band; NBM, nucleus basalis of Meynert; SI, substantia innominata; LDT, laterodorsal tegmental nucleus; PPT, pedunclopontine tegmental nucleus.

Table 1.

Summary of pharmacological evidence for cholinergic regulation of mood

Illness	Drug	Mechanism of action	Effect
Unipolar depression	Physostigmine	AChEI	Worsened depression ²²
	Arecoline	mAChR agonist	Worsened depression ¹⁸²
	Scopolamine	Antimuscarinic	Antidepressant ^{7, 9-11}
	Nicotine	nAChR agonist	Antidepressant in depressed non-smokers ¹³⁴
Bipolar depression	Physostigmine	AChEI	Worsened depression ²²
	Arecoline	mAChR agonist	Worsened depression ¹⁸²
	Scopolamine	Antimuscarinic	Antidepressant ^{7, 9-11}
Bipolar mania	Physostigmine	AChEI	Reduced mania ²²⁻²⁴
	RS 86	M1-AChR agonist	Reduced mania ⁹⁵
Controls	Physostigmine	AChEI	Induced depression in those with positive history ²⁵⁻²⁷ Induced depression in marijuana-intoxicated controls ⁹⁰
	Donepezil	AChEI	Induced depression in cognitively impaired with positive history ^{28, 29}
	Deanol	ACh precursor	Induced depression or hypomania in those with positive history ¹⁸³
	Choline	ACh precursor	Induced depression in tardive dyskinesia patients ³³
	Arecoline	mAChR agonist	Induced depression in controls and euthymic bipolars patients ⁹² , and Alzheimers disease ⁹³
	Oxotremorine	ACh agonist	Induced depression in Alzheimers disease ⁹⁴
	Nicotine	nAChR agonist	Antidepressant in non-smokers ¹³³

Abbreviations: ACh, acetylcholine; AChEI, acetylcholinesterase inhibitor; nAChR, nicotinic acetylcholine receptor; mAChR, muscarinic acetylcholine receptor; M1-AChR, muscarinic 1 acetylcholine receptor.

Table 2.

Effects of manipulations of the cholinergic system on depression-like behavior in rodents

Species	Drug	Mechanism	Route	Test	Effect
Mice	Physostigmine	AChEI	Systemic	FST	Depression-like ⁷⁶⁻⁷⁸
				TST	Depression-like ^{74, 78}
			Intra-VTA	FST	Depression-like ⁷⁵
			Intra-Hipp	TST	Depression-like ⁷⁴
				Social defeat	Depression-like ⁷⁴
	Scopolamine	Antimuscarinic	Systemic	FST	Antidepressant-like ¹¹⁸⁻¹²¹
				CMS	Antidepressant-like ¹¹⁹
				LH	Antidepressant-like ¹²²
				NSF	Antidepressant-like ^{118, 120}
				SP	Antidepressant-like ¹¹⁹
	Nicotine	nAChR agonist	Systemic	FST	Antidepressant-like ^{154, 156}
				TST	Antidepressant-like ^{154, 156}
	Mecamylamine	nAChR antagonist	Systemic	FST	Antidepressant-like ^{148, 156}
				TST	Antidepressant-like ¹⁵⁶
Methyllycaconite	a7 nAChR antagonist	Systemic	FST	Antidepressant-like ⁷⁶	
Varenicline	a4b2 nAChR partial agonist	Systemic	FST	Antidepressant-like ¹⁶⁰	
			TST	Antidepressant-like ⁷⁶	
Rats	Physostigmine	AChEI	Systemic	FST	Depression-like ⁷⁵
			Intra-VTA	SP	Depression-like ⁸⁴
	Pilocarpine	mAChR agonist	Intra-VTA	FST	Depression-like ⁸⁴
	Scopolamine	Antimuscarinic	Intra-VTA	FST	Antidepressant-like ⁷⁵
				Systemic	FST
	CMS	Antidepressant-like ¹⁵⁸			
	SP	Antidepressant-like ¹⁵⁸			
	Arecoline	mAChR agonist	Intra-NAc	FST	Depression-like ⁸⁶
	Pirenzepine	M1-AChR antagonist	Intra-NAc	FST	Antidepressant-like ^{86, 88}
	Gallamine	M2-AChR antagonist	Intra-NAc	FST	Depression-like ⁸⁶
	Scopolamine	Antimuscarinic	Intra-NAc	FST	Antidepressant-like ⁸⁶
				Systemic	FST
	Nicotine	nAChR agonist	OBX		Antidepressant-like ¹⁵⁵

Abbreviations: AChEI, acetylcholinesterase inhibitor; nAChR, nicotinic acetylcholine receptor; mAChR, muscarinic acetylcholine receptor; M1-AChR, muscarinic 1 acetylcholine receptor; Intra-VTA, intra-ventral tegmental area; Intra-Hipp, intra-hippocampal; Intra-NAc, intra-nucleus accumbens; FST, forced swim test; TST, tail suspension test; SP, sucrose preference; CMS, chronic mild stress; LH, learned helplessness; NSF, novelty suppressed feeding.